CIRCULOGENE’s TumorClear next generation sequencing (NGS) panel includes guideline markers, as well as, expert recommended actionable DNA mutations.
The TumorClear NGS panel provides a molecular profile which can help your doctor to prescribe targeted treatment at the time of diagnosis, understand your response to treatment, and/or monitor cancer progression and recurrence.
CIRCULOGENE offers the ONLY liquid cfRNA PD-L1, ImmunoClear. Patients with PD-L1 have been known to respond positively to immunotherapy versus chemotherapy. Should you have a PD-L1 expression, your doctor will consider this with other markers and your overall health in order to determine the right treatment for you.